Efficacy Study of add-on Therapy With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if N-Acetylcysteine (NAC) has efficacy as
an augmentation agent in the treatment of treatment-resistant obsessive-compulsive disorder
(OCD). The investigators predict that NAC will reduce OCD symptoms after sixteen weeks of
add-on treatment as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
Phase:
Phase 2
Details
Lead Sponsor:
University of Sao Paulo
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo